Skip to main content
MCIC logo

Multicorp International, Inc. (MCIC) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0002 $0.00 (0.00%)
Vol: 5.8K| 52-wk range: $0.0001 – $0.007
Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Multicorp International, Inc. (MCIC) trades at $0.0002. MultiCorp International, Inc. focuses on identifying and acquiring companies in the medical and technical sectors. Currently, the company does not have significant operations. Sector: Healthcare.

Price as of · Last analyzed: Mar 17, 2026
MultiCorp International, Inc. focuses on identifying and acquiring companies in the medical and technical sectors. Currently, the company does not have significant operations.

Analyst Coverage for MCIC: MCIC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ACH · Accendra Health, Inc. · 30 /100
  • PBH · Prestige Consumer Healthcare Inc. · 63 /100
  • GRDN · Guardian Pharmacy Services, Inc. · 96 /100

See all scored stocks →

Multicorp International, Inc. (MCIC) Healthcare & Pipeline Overview

CEODavid Gustafson
HeadquartersAgoura Hills, US
IPO Year1997

MultiCorp International, Inc. is a holding company focused on acquiring businesses in the medical and technical sectors, currently without significant operational activities. Operating within the Drug Manufacturers - Specialty & Generic industry, the company seeks to grow through strategic acquisitions, but faces risks inherent to OTC markets and acquisition-dependent business models.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 17, 2026

What Is the Investment Thesis for MCIC?

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

MultiCorp International, Inc. presents a speculative investment opportunity centered on its ability to execute strategic acquisitions in the medical and technical sectors. The company's value is currently tied to its potential to acquire and grow promising businesses. A key value driver is the successful identification and integration of target companies that can generate revenue and profit. However, the company's lack of current operations and reliance on future acquisitions introduces significant risk. Investors should monitor the company's acquisition activity, financial performance of acquired entities, and ability to secure funding for future deals. Given the negative P/E ratio of -36.59 and high beta of 6.79, MCIC is a high-risk investment.

Based on FMP financials and quantitative analysis

MCIC Key Highlights

AI-written as of Mar 17, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $0.00B indicates a micro-cap status and limited market presence.

  • Negative P/E ratio of -36.59 reflects current unprofitability, suggesting the company is not generating positive earnings.
  • Beta of 6.79 indicates extremely high volatility compared to the market average, implying a higher degree of investment risk.
  • The company's focus on acquisitions differentiates it from traditional pharmaceutical companies that focus on R&D and manufacturing.
  • Lack of dividend payout reflects the company's current stage of development and focus on reinvesting capital for growth.

Who Are MCIC's Competitors?

MCIC is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
ACH Accendra Health, Inc. $0.09 -35.08% $6.60M 30 5-pillar
PBH Prestige Consumer Healthcare Inc. $50.62 +4.98% $2.40B 63 5-pillar
GRDN Guardian Pharmacy Services, Inc. $48.83 -2.98% $3.09B 96 5-pillar
HSIC Henry Schein, Inc. $85.69 +3.32% $9.47B 73 5-pillar
CAH Cardinal Health, Inc. $278.35 -0.32% $64.3B 88 5-pillar
COR Cencora, Inc. $348.28 -0.65% $66.5B 86 5-pillar
MCK McKesson Corporation $1084.43 -0.66% $125B 92 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MCIC's Key Strengths?

Focus on high-growth sectors (medical and technical).

  • Acquisition-based growth strategy allows for rapid expansion.
  • Potential for portfolio diversification and risk reduction.
  • Experienced management team with deal-making expertise (assumed).

What Are MCIC's Weaknesses?

Lack of current operations and revenue generation.

  • Reliance on future acquisitions for growth.
  • High dependence on external financing for acquisitions.
  • Integration challenges associated with acquired companies.

What Are the Key Risks for MCIC?

Financial-distress signal — its Altman Z-Score of 0.88 sits in the distress zone (elevated bankruptcy risk).

  • Negative return on equity (-0.6%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
  • Failure to identify and acquire suitable target companies.
  • Inability to secure financing for acquisitions.
  • Integration challenges and potential for failed acquisitions.
  • Regulatory hurdles and pricing pressures in the healthcare industry.
  • Economic downturns impacting acquisition financing and the performance of acquired companies.

What Are MCIC's Competitive Advantages?

  • Deal-making expertise: MCIC's ability to identify, negotiate, and close strategic acquisitions could provide a competitive advantage.
  • Portfolio diversification: A diversified portfolio of acquired companies can reduce risk and provide multiple revenue streams.
  • Synergies between acquired entities: MCIC can create value by fostering synergies and collaboration between its acquired companies.

What Does MCIC Do?

MultiCorp International, Inc., formerly known as XTend Medical Corporation, transitioned to its current focus in August 2012. Headquartered in Agoura Hills, California, the company's primary strategy involves identifying and acquiring businesses within the medical and technical sectors. Unlike typical pharmaceutical companies that engage in research, development, and manufacturing, MultiCorp International operates as a holding company, seeking to build a portfolio of companies through strategic acquisitions. As of 2026, the company does not have significant operations, indicating it is in the early stages of executing its acquisition-based growth strategy. The company's success hinges on its ability to identify, acquire, and integrate promising businesses, navigate the complexities of the healthcare and technology landscapes, and secure necessary funding for its acquisition activities. Its competitive positioning is therefore dependent on its deal-making capabilities and the performance of its acquired entities.

What Products and Services Does MCIC Offer?

  • Identifies companies operating in the medical sector.
  • Identifies companies operating in the technical sector.
  • Focuses on acquiring companies rather than internal development.
  • Operates as a holding company for acquired businesses.
  • Seeks to build a portfolio of companies through acquisitions.
  • Aims to generate revenue and profit through acquired entities.
  • Manages and integrates acquired companies into its portfolio.

How Does MCIC Make Money?

  • Acquisition-based growth: MCIC's primary business model revolves around acquiring companies in the medical and technical sectors.
  • Holding company structure: MCIC operates as a holding company, managing a portfolio of acquired businesses.
  • Revenue generation through acquired entities: MCIC generates revenue and profit through the operations of its acquired companies.

What Industry Does MCIC Operate In?

MultiCorp International operates within the Drug Manufacturers - Specialty & Generic industry, a segment characterized by companies that develop, manufacture, and market pharmaceutical products. However, MCIC's acquisition-focused strategy distinguishes it from peers that are primarily engaged in R&D and manufacturing. The industry is subject to regulatory scrutiny, patent expirations, and pricing pressures. The competitive landscape includes established generic drug manufacturers and specialty pharmaceutical companies. MCIC's success depends on its ability to identify and acquire companies with promising products or technologies within this dynamic environment.

Who Are MCIC's Key Customers?

  • MCIC's customers are the end-users of the products and services offered by its acquired companies.
  • These customers may include patients, healthcare providers, hospitals, and other healthcare organizations.
  • The specific customer segments depend on the nature of the businesses acquired by MCIC.
Model self-rating on this text: 69% (not a measure of the evidence) Updated: Mar 17, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Multicorp International, Inc. operates in the Healthcare sector. It is headquartered in Agoura Hills, US. The company is led by CEO David Gustafson. MCIC has traded publicly since 1997.

ROE -1%

Key Financial Metrics

Return on equity for Multicorp International, Inc. stands at -0.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9

Financial Health

Multicorp International, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.88 places it in the distress zone, a signal of elevated financial risk.

MCIC Latest News

No recent news available for MCIC.

MCIC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MCIC.

Price Targets

Wall Street price target analysis for MCIC.

MCIC MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MCIC; grades run from A+ (80-100) to F (below 30).

Leadership: David Gustafson

CEO

Without additional context, it is impossible to provide details about his career history, education, or previous roles. Further research would be required to develop a comprehensive profile.

Track Record: Information on David Gustafson's track record is not available in the provided data. Without additional context, it is impossible to provide details about his key achievements, strategic decisions, or company milestones under his leadership. Further research would be required to assess his performance.

MCIC OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that MultiCorp International, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information, price volatility, and illiquidity.

  • OTC Tier: OTC Other
Liquidity: Liquidity on the OTC market, particularly for the OTC Other tier, can be highly variable. Given the lack of information on MCIC's trading volume and bid-ask spread, it is difficult to assess the stock's liquidity. However, it is likely that the stock experiences low trading volume and a wide bid-ask spread, making it difficult to buy or sell shares quickly and at a favorable price. This illiquidity can increase the risk of significant price fluctuations.
OTC Risk Factors:
  • Limited information and disclosure: OTC companies may not be required to provide the same level of financial information as companies listed on major exchanges.
  • Low liquidity: OTC stocks often have low trading volume and wide bid-ask spreads, making it difficult to buy or sell shares.
  • Price volatility: OTC stocks can be subject to significant price fluctuations due to limited trading activity and information.
  • Potential for fraud and manipulation: The OTC market is more susceptible to fraud and manipulation than major exchanges.
  • Going Concern Risk: Companies on the OTC Other tier may have financial difficulties, increasing the risk of business failure.
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's liquidity and trading volume.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before investing.
  • Check for any regulatory actions or legal issues involving the company.
Legitimacy Signals:
  • Independent audits of financial statements (if available).
  • Experienced management team with a proven track record (if verifiable).
  • Clear and transparent business model.
  • Active communication with shareholders (if any).
  • Compliance with regulatory requirements (if any).

Common Questions About MCIC (Healthcare)

What do analysts say about MCIC stock?

As of March 17, 2026, there is no available analyst coverage for MultiCorp International, Inc. due to its micro-cap status and lack of significant operations. Key valuation metrics, such as revenue, earnings, and cash flow, are currently not applicable.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited information available on MultiCorp International, Inc. due to its micro-cap status and lack of significant operations.
  • OTC market investments carry significant risks.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives